Tarsus Pharmaceuticals, Inc. is a leading biopharmaceutical company that has demonstrated its industry leadership by developing XDEMVY™, the first and only FDA approved treatment for Demodex Blepharitis. The company's culture fosters scientific excellence and technological advancement, as evidenced by their application of new technology to proven science in eye care. Tarsus' competitive advantage lies in its unique ability to identify and address unmet medical needs, positioning it as a pioneer in the biopharmaceutical industry.